205 related articles for article (PubMed ID: 9491842)
1. Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients?
Kralovicová K; Spanik S; Halko J; Netriova J; Studena-Mrazova M; Novotny J; Grausova S; Koren P; Krupova I; Demitrovicova A; Kukuckova E; Krcmery V
J Chemother; 1997 Dec; 9(6):420-6. PubMed ID: 9491842
[TBL] [Abstract][Full Text] [Related]
2. Do low vancomycine serum levels predict failures of vancomycine therapy in neutropenic cancer patients?
Netriová J; Hal'ko J; Studená-Mrázová M; Kukucková E; Stopková K; Kral'ovicová K; Demitrovicová A; Grausová S; Krupová I; Trupl J; Krcméry V
Bratisl Lek Listy; 1996 Nov; 97(11):680-3. PubMed ID: 9117433
[TBL] [Abstract][Full Text] [Related]
3. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia.
Zimmermann AE; Katona BG; Plaisance KI
Pharmacotherapy; 1995; 15(1):85-91. PubMed ID: 7739950
[TBL] [Abstract][Full Text] [Related]
4. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy.
Pauly DJ; Musa DM; Lestico MR; Lindstrom MJ; Hetsko CM
Pharmacotherapy; 1990; 10(6):378-82. PubMed ID: 2287556
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of risk factors for vancomycin-induced nephrotoxicity.
Park SJ; Lim NR; Park HJ; Yang JW; Kim MJ; Kim K; In YW; Lee YM
Int J Clin Pharm; 2018 Oct; 40(5):1328-1334. PubMed ID: 29744794
[TBL] [Abstract][Full Text] [Related]
6. High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis.
Meng L; Fang Y; Chen Y; Zhu H; Long R
J Chemother; 2015 Aug; 27(4):213-20. PubMed ID: 24641266
[TBL] [Abstract][Full Text] [Related]
7. Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study.
Matson KL; Shaffer CL; Beck GL; Simonsen KA
Pharmacotherapy; 2015 Mar; 35(3):337-43. PubMed ID: 25756622
[TBL] [Abstract][Full Text] [Related]
8. Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study.
Bhatt-Mehta V; Schumacher RE; Faix RG; Leady M; Brenner T
Pediatrics; 1999 Apr; 103(4):e48. PubMed ID: 10103340
[TBL] [Abstract][Full Text] [Related]
9. Incidence and predictors of vancomycin-associated nephrotoxicity.
Moh'd H; Kheir F; Kong L; Du P; Farag H; Mohamad A; Zurlo JJ
South Med J; 2014 Jun; 107(6):383-8. PubMed ID: 24945176
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study.
Barberan J; Mensa J; Artero A; Epelde F; Rodriguez JC; Ruiz-Morales J; Calleja JL; Guerra JM; Martínez-Gil I; Giménez MJ; Granizo JJ; Aguilar L
Rev Esp Quimioter; 2019 Feb; 32(1):22-30. PubMed ID: 30630306
[TBL] [Abstract][Full Text] [Related]
11. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring.
Han HK; An H; Shin KH; Shin D; Lee SH; Kim JH; Cho SH; Kang HR; Jang IJ; Yu KS; Lim KS
Ther Drug Monit; 2014 Oct; 36(5):606-11. PubMed ID: 24577126
[TBL] [Abstract][Full Text] [Related]
12. Nephrotoxicity due to combination antibiotic therapy with vancomycin and aminoglycosides in septic critically ill patients.
Malacarne P; Bergamasco S; Donadio C
Chemotherapy; 2006; 52(4):178-84. PubMed ID: 16691027
[TBL] [Abstract][Full Text] [Related]
13. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 μg/ml in a pediatric intensive care unit.
Cies JJ; Shankar V
Pharmacotherapy; 2013 Apr; 33(4):392-400. PubMed ID: 23471688
[TBL] [Abstract][Full Text] [Related]
14. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.
Cano EL; Haque NZ; Welch VL; Cely CM; Peyrani P; Scerpella EG; Ford KD; Zervos MJ; Ramirez JA; Kett DH;
Clin Ther; 2012 Jan; 34(1):149-57. PubMed ID: 22284995
[TBL] [Abstract][Full Text] [Related]
15. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort.
Kullar R; Davis SL; Taylor TN; Kaye KS; Rybak MJ
Pharmacotherapy; 2012 Mar; 32(3):195-201. PubMed ID: 22392452
[TBL] [Abstract][Full Text] [Related]
16. The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis.
Horey A; Mergenhagen KA; Mattappallil A
Ann Pharmacother; 2012 Nov; 46(11):1477-83. PubMed ID: 23073306
[TBL] [Abstract][Full Text] [Related]
17. The Whole Price of Vancomycin: Toxicities, Troughs, and Time.
Jeffres MN
Drugs; 2017 Jul; 77(11):1143-1154. PubMed ID: 28573434
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of body weight-based vancomycin therapy and the incidence of nephrotoxicity: a retrospective study in the northwest of China.
Dong MH; Wang JW; Wu Y; Chen BY; Yu M; Wen AD
Int J Infect Dis; 2015 Aug; 37():125-8. PubMed ID: 26159843
[TBL] [Abstract][Full Text] [Related]
19. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
Lodise TP; Patel N; Lomaestro BM; Rodvold KA; Drusano GL
Clin Infect Dis; 2009 Aug; 49(4):507-14. PubMed ID: 19586413
[TBL] [Abstract][Full Text] [Related]
20. Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy.
Nahata MC
Chemotherapy; 1987; 33(4):302-4. PubMed ID: 3608631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
